Deoxyfuconojirimycin

Deoxyfuconojirimycin

SCHEMBL1867289

CC1NCC(O)C(O)C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 5/20 1.00
FUCA2 Q9BTY2 1/20 1.00
GLB1 P16278 1/20 0.58
GBA1 P04062 5/20 0.54
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
GANAB Q14697 1/20 0.46
MAN2B1 O00754 1/20 0.46
MAN2B2 Q9Y2E5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deoxyfuconojirimycin SCHEMBL15686574 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA
Deoxyfuconojirimycin SCHEMBL13876082 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA
Deoxyfuconojirimycin SCHEMBL4378188 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA
Deoxyfuconojirimycin SCHEMBL12581516 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA
Deoxyfuconojirimycin SCHEMBL9999893 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA
Deoxyfuconojirimycin SCHEMBL13328524 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA
Deoxyfuconojirimycin SCHEMBL2436650 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA
Deoxyfuconojirimycin SCHEMBL15691930 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA
Deoxyfuconojirimycin SCHEMBL13876087 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA
Deoxyfuconojirimycin SCHEMBL2435560 1.00 FUCA1 (1.00) FUCA1FUCA2GLB1GBA1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 CN claimed
CN-114174263-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2022-03-11 CN claimed
US-20030204091-A1 Process for the preparation of 1, 5-dideoxy-1,5-imino hexitols from oximes or imines MICHIGAN STATE UNIVERSITY 2003-10-30 US claimed
US-20030109710-A1 PROCESS FOR THE PREPARATION OF 1,5-DIDEOXY-1,5-IMINO HEXITOLS FROM OXIMES OR IMINES BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2003-06-12 US claimed
US-6462197-B2 REACTING A KETOALDONIC ACID METHYL ESTER OF THE SUGAR WITH THE PROTECTED HYDROXYL GROUPS WITH AN ALKYLAMINE OR HYDROXYAMINE ACID SALT WITH A TERTIARY AMINE TO REACT WITH AN ACID GENERATED IN THE REACTION TO PRODUCE OXIME METHYL ESTER BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2002-10-08 US claimed
US-20020068819-A1 Process for the preparation of 1,5-dideoxy-1, 5-imino hexitols from oximes or imines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2002-06-06 US claimed
US-20020052506-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2002-05-02 US claimed
US-20020052505-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2002-05-02 US claimed
US-20020016447-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2002-02-07 US claimed
US-20020016448-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY 2002-02-07 US claimed
US-20010049443-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2001-12-06 US claimed
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 US disclosed
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 CN disclosed
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2022-07-07 US disclosed
CN-114174263-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2022-03-11 CN disclosed
EP-0884050-A1 Use of 3,4-dihydroxy-2-hydroxymethylpyrrolidine for the treatment of diabetes NOVO NORDISK A/S (DK) 1998-12-16 EP disclosed
EP-0858335-A1 2-ALKYLPYRROLIDINES NOVO NORDISK A/S (DK) 1998-08-19 EP disclosed
WO-1997009040-A1 2-ALKYLPYRROLIDINES NOVO NORDISK A/S (DK) 1997-03-13 WO disclosed
EP-0749423-A1 PIPERIDINES AND PYRROLIDINES NOVO NORDISK A/S (DK) 1996-12-27 EP disclosed
WO-1995024391-A1 PIPERIDINES AND PYRROLIDINES NOVO NORDISK A/S (DK) 1995-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016448-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines GALE, HK1, G6PD FUCA1 1170/4885FUCA2 870/4885GLB1 380/4885
US-20010049443-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines GALE, HK1, G6PD FUCA1 1053/4885FUCA2 756/4885GLB1 354/4885
US-20030109710-A1 PROCESS FOR THE PREPARATION OF 1,5-DIDEOXY-1,5-IMINO HEXITOLS FROM OXIMES OR IMINES GALE, HK1, G6PD FUCA1 1170/4885FUCA2 870/4885GLB1 380/4885
US-20020052506-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines GALE, HK1, G6PD FUCA1 1170/4885FUCA2 870/4885GLB1 380/4885
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA FUCA1 66/4885FUCA2 61/4885GLB1 78/4885
US-20020068819-A1 Process for the preparation of 1,5-dideoxy-1, 5-imino hexitols from oximes or imines GALE, HK1, G6PD FUCA1 1170/4885FUCA2 870/4885GLB1 380/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 FUCA1 22/4885FUCA2 23/4885GLB1 48/4885
US-20020016447-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines GALE, HK1, G6PD FUCA1 1170/4885FUCA2 870/4885GLB1 380/4885
US-20030204091-A1 Process for the preparation of 1, 5-dideoxy-1,5-imino hexitols from oximes or imines GALE, HK1, G6PD FUCA1 1170/4885FUCA2 870/4885GLB1 380/4885
US-20020052505-A1 Process for the preparation of 1,5-dideoxy-1,5-imino hexitols from oximes or imines GALE, HK1, G6PD FUCA1 1170/4885FUCA2 870/4885GLB1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.